Everything the project writes is published here as it is written, drafts included.
A draft is published at the point where it is useful to argue with, not when it is finished. The research agenda is circulated for exactly that reason: it is open for correction until 1 January 2027, and every direction in it names the cheapest test that would advance or kill it. Corrections to anything here are welcome and credited.
Six research tracks and 45 directions for the brain and spine compartment, each with a confidence tier, the lever it pulls and the cheapest test. A first draft, circulated for input until 1 January 2027. Web version.
Why brain and spine hemangioblastoma needs its own money: where the research actually goes, what changed for the kidney and did not for the brain, what patients carry, and the questions clinicians ask. Web version.
One patient, eight lesions, five years on drug; a voxel-level re-measurement of a complete 2015–2026 imaging archive, and why diameter-based criteria can report progression in a lesion that may be responding. Web version.
A synthesis of lifetime CNS procedure counts, the functional-stability curve, and the only published dose-response between surgery count and quality of life — the evidence base for the project's primary outcome.
A discussion paper on response assessment for an anti-vascular drug in a benign, encapsulated, fluid-accumulating tumor.